Imagion Biosystems Limited Stock

Equities

IBX

AU000000IBX6

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 12:50:03 2024-03-28 am EDT 5-day change 1st Jan Change
0.074 AUD -9.76% Intraday chart for Imagion Biosystems Limited -.--% -79.15%
Sales 2021 2.86M 1.83M Sales 2022 3.07M 1.97M Capitalization 26.91M 17.27M
Net income 2021 -6M -3.85M Net income 2022 -9M -5.78M EV / Sales 2021 25.2 x
Net cash position 2021 13.35M 8.57M Net Debt 2022 158K 102K EV / Sales 2022 8.81 x
P/E ratio 2021
-12.7 x
P/E ratio 2022
-2.67 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 91.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day-9.76%
1 month-8.64%
3 months-67.83%
6 months-84.58%
Current year-79.15%
More quotes
1 month
0.07
Extreme 0.073
0.08
Current year
0.07
Extreme 0.073
0.36
1 year
0.07
Extreme 0.073
1.44
3 years
0.07
Extreme 0.073
6.20
5 years
0.07
Extreme 0.073
9.00
10 years
0.07
Extreme 0.073
9.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 20-12-07
Chairman 66 -
Chief Operating Officer - 21-10-31
Members of the board TitleAgeSince
Director/Board Member 74 17-03-07
Chairman 66 -
Director/Board Member 69 17-02-27
More insiders
Imagion Biosystems Limited is a medical imaging company engaged in developing medical imaging technologies for various cancer types. The Company uses bio-safe magnetic nanoparticles to detect cancer and other diseases. Its principal activity consists of nanotechnology, biotechnology, cancer diagnostics and medical imaging using magnetic resonance. The Company operates through Research and Development segment. It is advancing clinical development of its MagSense platform technology to revolutionize cancer diagnosis, introducing molecular imaging to Magnetic resonance imaging (MRI). The Company’s lead program has demonstrated its technology embodied in MagSense HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Its MagSense pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.
More about the company